Pharmacotherapy for post traumatic stress disorder (PTSD)

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Psychology

Background:

• Posttraumatic stress disorder (PTSD) is a significant mental health condition with a growing interest in pharmacological interventions.
• Understanding the psychobiological underpinnings of PTSD fuels research into effective medication treatments.

Purpose of the Study:

• To systematically evaluate the efficacy of various medications in alleviating PTSD symptoms among adults.
• To synthesize evidence from randomized controlled trials (RCTs) on pharmacotherapy for PTSD.

Main Methods:

• Conducted a comprehensive literature search across multiple databases including CENTRAL, MEDLINE, Embase, PsycINFO, and PTSDPubs up to November 2020.
• Included 66 RCTs involving 7442 participants in the review and 54 RCTs in the meta-analysis.
• Assessed trial quality, collated data, and performed stratified analyses by medication class and agent using random-effects models.

Main Results:

• Selective serotonin reuptake inhibitors (SSRIs) demonstrated a beneficial effect in improving PTSD symptoms compared to placebo (moderate-certainty evidence).
• Mirtazapine (a noradrenergic and specific serotonergic antidepressant) and amitriptyline (a tricyclic antidepressant) also showed potential benefits, though based on low-certainty evidence.
• Antipsychotics did not show evidence of benefit for improving PTSD symptoms compared to placebo (very low-certainty evidence), and SSRIs were associated with increased treatment withdrawal.

Conclusions:

• SSRIs are supported as first-line pharmacotherapy for PTSD due to their efficacy in symptom reduction.
• Mirtazapine and amitriptyline may offer therapeutic benefits, but further high-quality research is necessary.
• The current evidence highlights the need for continued research to identify more effective treatments for PTSD.